Key result
Modified shock index ≥0.93 at presentation predicts ~100% higher six-month mortality in STEMI patients.
Why the study?
Prompt identification of higher-risk STEMI patients at presentation is crucial to guide more aggressive treatment approaches, but effective bedside risk assessment tools are needed.
Does a modified shock index (MSI) ≥ 0.93 predict six-month mortality in patients presenting with STEMI without cardiogenic shock?
Cohort (n=1,158)
No
Does a modified shock index (MSI) ≥ 0.93 predict six-month mortality in patients presenting with STEMI without cardiogenic shock?
A modified shock index ≥ 0.93 at presentation is a simple bedside tool that independently predicts six-month mortality in STEMI patients without cardiogenic shock.
Answers are grounded in this paper and cite their sources.
May aid bedside risk stratification in STEMI; hypothesis-generating pending prospective validation.
Introduction Prompt identification of higher-risk patients presenting with ST-segment elevation myocardial infarction (STEMI) is crucial to pursue a more aggressive approach. Objective We aimed to assess whether the modified shock index (MSI), the ratio of heart rate to mean arterial pressure, could predict six-month mortality among patients admitted with STEMI. Methods A retrospective observational cohort study was performed in a single center including 1158 patients diagnosed with STEMI, without cardiogenic shock on admission, between July 2009 and December 2014. They were divided into two groups: group 1 – patients with MSI < 0.93 (72%); group 2 – patients with MSI≥0.93 (28%). The primary endpoint was six-month all-cause mortality. Results MSI≥0.93 identified patients who were more likely to have signs of heart failure (p=0.002), anemia (p < 0.001), renal insufficiency (p=0.014) and left ventricular systolic dysfunction (p=0.045). They more often required inotropic support (p < 0.001), intra-aortic balloon pump (p < 0.001) and mechanical ventilation (p < 0.001). Regarding in-hospital adverse events, they had a higher prevalence of malignant arrhythmias (p=0.01) and mechanical complications (p=0.027). MSI≥0.93 was an independent predictor of overall six-month mortality (adjusted HR 2.00, 95% CI 1.20-3.34, p=0.008). Conclusion MSI was shown to be a valuable bedside tool which can rapidly identify high-risk STEMI patients at presentation.
No takes yet. Share an insight, caveat, or question.
Abreu et al. (2018) conducted a cohort in ST-segment elevation myocardial infarction (STEMI) (n=1,158). Modified shock index (MSI) ≥0.93 vs. MSI <0.93 was evaluated on six-month all-cause mortality (HR 2.00, 95% CI 1.20-3.34, p=0.008). A modified shock index ≥0.93 at presentation was an independent predictor of six-month all-cause mortality in STEMI patients.
Synapse has enriched 10 related papers. Consider them for comparative context: